Empagliflozin/linagliptin combination therapy: The way forward in the joint management of diabetes and cardiovascular disease

01 Apr 2022
Empagliflozin/linagliptin combination therapy:
The way forward in the joint management of
diabetes and cardiovascular disea
Cardiovascular disease (CVD) is a common comorbidity in diabetes mellitus (DM) and its prevalence is on the rise. Studies have reported that several factors including oxidative stress, low-grade inflammation, endothelial dysfunction and autonomic neuropathy are often present in patients with DM, and may directly contribute to the increased prevalence of myocardial infarction (MI), coronary revascularisation, stroke and congestive heart failure (HF).1,2 The presence of both DM and CVD in patients increases the risk of mortality and morbidity among men and women alike.

Related MIMS Drugs

Editor's Recommendations